BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Teva Neuroscience, Inc. 

901 E. 104th Street
Suite 900
Kansas City  Missouri  64131  U.S.A.
Phone: 800-221-4026 or 816-508-5000
Fax: 816-508-5016


SEARCH JOBS




Industry
Pharmaceutical






 Company News
Topin & Associates Selects an Account Supervisor to Manage Teva Neuroscience, Inc. (TEVA)'s Global Brand 12/3/2012 11:25:35 AM    More...
Teva Neuroscience, Inc. (TEVA) Will Take 100 Jobs from KC to OP 4/5/2012 7:27:45 AM    More...
Teva Neuroscience, Inc. (TEVA) Release: Recently Published Clinical Pharmacology Study Confirms Azilect(R) Selectively Inhibits MAO-B at Approved Doses 6/2/2010 10:29:12 AM    More...
BioScrip (BIOS) Commences Patient Enrollment in Teva Neuroscience, Inc. (TEVA) Therapy Optimization in Multiple Sclerosis (Tops MS) Research Study 6/30/2009 9:49:30 AM    More...
Teva Neuroscience, Inc. (TEVA): Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity 6/9/2009 11:25:23 AM    More...
Teva Neuroscience, Inc. (TEVA) Release: COPAXONE(R) Significantly Reduced Brain Atrophy and Tissue Loss over Five Years in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients 4/18/2008 7:46:56 AM    More...
Teva Neuroscience, Inc. (TEVA): Study Showed Patients Using COPAXONE® Had Significantly Lower Risk of Relapse and Lower Medical Costs Compared to Patients Using Rebif® in Relapsing-Remitting Multiple Sclerosis (RRMS) 10/25/2007 9:42:21 AM    More...
Teva Neuroscience, Inc. (TEVA): New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated COPAXONE(R) is More Cost Effective Than Tysabri(R) for Treatment of Relapsing-Remitting Multiple Sclerosis 10/25/2007 9:36:41 AM    More...
Teva Neuroscience, Inc. (TEVA) Release: International Movement Disorder Specialists Receive New Information About the Use of Once-Daily AZILECT(R) in the Treatment of Parkinson's Disease 6/8/2007 12:58:27 PM    More...
Treatment with Teva Neuroscience, Inc. (TEVA)'s COPAXONE(R) Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis 5/4/2007 1:21:33 PM    More...
12345